BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 29460025)

  • 1. Combined model-based and patient-specific dosimetry for
    Plyku D; Mena E; Rowe SP; Lodge MA; Szabo Z; Cho SY; Pomper MG; Sgouros G; Hobbs RF
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):989-998. PubMed ID: 29460025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [
    Werner RA; Bundschuh RA; Bundschuh L; Lapa C; Yin Y; Javadi MS; Buck AK; Higuchi T; Pienta KJ; Pomper MG; Lodge MA; Gorin MA; Rowe SP
    Mol Imaging Biol; 2020 Feb; 22(1):190-197. PubMed ID: 31140110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [
    Sahakyan K; Li X; Lodge MA; Werner RA; Bundschuh RA; Bundschuh L; Kulkarni HR; Schuchardt C; Baum RP; Pienta KJ; Pomper MG; Ross AE; Gorin MA; Rowe SP
    Mol Imaging Biol; 2020 Feb; 22(1):181-189. PubMed ID: 31115751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution and radiation dosimetry of [
    Hohberg M; Kobe C; Krapf P; Täger P; Hammes J; Dietlein F; Zlatopolskiy BD; Endepols H; Wild M; Neubauer S; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
    EJNMMI Res; 2019 Jul; 9(1):66. PubMed ID: 31346821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
    Szabo Z; Mena E; Rowe SP; Plyku D; Nidal R; Eisenberger MA; Antonarakis ES; Fan H; Dannals RF; Chen Y; Mease RC; Vranesic M; Bhatnagar A; Sgouros G; Cho SY; Pomper MG
    Mol Imaging Biol; 2015 Aug; 17(4):565-74. PubMed ID: 25896814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semiquantitative Parameters in PSMA-Targeted PET Imaging with
    Li X; Rowe SP; Leal JP; Gorin MA; Allaf ME; Ross AE; Pienta KJ; Lodge MA; Pomper MG
    J Nucl Med; 2017 Jun; 58(6):942-946. PubMed ID: 27932557
    [No Abstract]   [Full Text] [Related]  

  • 8. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.
    Zechmann CM; Afshar-Oromieh A; Armor T; Stubbs JB; Mier W; Hadaschik B; Joyal J; Kopka K; Debus J; Babich JW; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1280-92. PubMed ID: 24577951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraindividual Comparison of
    Giesel FL; Will L; Lawal I; Lengana T; Kratochwil C; Vorster M; Neels O; Reyneke F; Haberkon U; Kopka K; Sathekge M
    J Nucl Med; 2018 Jul; 59(7):1076-1080. PubMed ID: 29269569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
    Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG
    Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
    Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
    Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Internal Dosimetry of 18 F-PSMA-1007 and 68 Ga-PSMA-11-HBED-CC.
    Sharma P; Watts A; Singh H
    Clin Nucl Med; 2022 Nov; 47(11):948-953. PubMed ID: 35961365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
    Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biokinetics and dosimetry of
    Hvittfeldt E; Bjöersdorff M; Brolin G; Minarik D; Svegborn SL; Oddstig J; Trägårdh E
    Clin Physiol Funct Imaging; 2022 Nov; 42(6):443-452. PubMed ID: 36039853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-individual comparison of
    Ferreira G; Iravani A; Hofman MS; Hicks RJ
    Cancer Imaging; 2019 May; 19(1):23. PubMed ID: 31092293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.
    Pfob CH; Ziegler S; Graner FP; Köhner M; Schachoff S; Blechert B; Wester HJ; Scheidhauer K; Schwaiger M; Maurer T; Eiber M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1962-70. PubMed ID: 27207281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.
    Afshar-Oromieh A; Hetzheim H; Kübler W; Kratochwil C; Giesel FL; Hope TA; Eder M; Eisenhut M; Kopka K; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1611-20. PubMed ID: 27260521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma.
    Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
    Clin Nucl Med; 2018 May; 43(5):323-330. PubMed ID: 29485430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Test-retest repeatability of organ uptake on PSMA-targeted
    Werner RA; Lütje S; Habacha B; Bundschuh L; Higuchi T; Buck AK; Kosmala A; Lapa C; Essler M; Lodge MA; Pienta KJ; Eisenberger MA; Markowski MC; Gorin MA; Pomper MG; Rowe SP; Bundschuh RA
    Prostate; 2023 Sep; 83(12):1186-1192. PubMed ID: 37211963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.